Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers

NCT07399171 is registered in ClinicalTrials.gov with Halia Therapeutics, Inc. as lead sponsor.

NCT NCT07399171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07399171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers
Lead sponsor
Halia Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 12, 2026
Completion date
July 31, 2028
Enrollment
112 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimers disease